Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average) (2021 - 2023)

Historic Shares Outstanding (Diluted Average) for Gyre Therapeutics (GYRE) over the last 6 years, with Q3 2023 value amounting to $38.0 million.

  • Gyre Therapeutics' Shares Outstanding (Diluted Average) rose 2015.74% to $38.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.0 million, marking a year-over-year increase of 2015.74%. This contributed to the annual value of $31.5 million for FY2022, which is 295.27% up from last year.
  • As of Q3 2023, Gyre Therapeutics' Shares Outstanding (Diluted Average) stood at $38.0 million, which was up 2015.74% from $37.8 million recorded in Q2 2023.
  • Gyre Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $38.0 million for Q1 2023, and its period low was $30.6 million during Q4 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $31.5 million (2022), whereas its average is $33.3 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 42.85% in 2022, and later skyrocketed by 2075.35% in 2023.
  • Quarter analysis of 3 years shows Gyre Therapeutics' Shares Outstanding (Diluted Average) stood at $30.6 million in 2021, then grew by 2.95% to $31.5 million in 2022, then increased by 20.39% to $38.0 million in 2023.
  • Its Shares Outstanding (Diluted Average) stands at $38.0 million for Q3 2023, versus $37.8 million for Q2 2023 and $38.0 million for Q1 2023.